NCT05664919 is a NA clinical trial of SA58 Nasal Spray in COVID-19, sponsored by Sinovac Life Sciences Co., Ltd..

Who is sponsoring NCT05664919?

NCT05664919 is sponsored by Sinovac Life Sciences Co., Ltd..

What drugs are being tested in NCT05664919?

Interventions in NCT05664919: SA58 Nasal Spray.

Is NCT05664919 still recruiting?

NCT05664919 is currently status unknown. Last updated 12 January 2023.

Last reviewed 2023-01-12 · How we verify

NCT05664919

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray to Prevent Infection in High-risk Populations

Status unknown NA Last updated 12 January 2023

What this trial tests

NA trial testing SA58 Nasal Spray in COVID-19 in 7,000 participants. Status unknown.

Timeline

30 October 2022

Primary endpoint
31 December 2022

31 March 2023

Quick facts

Lead sponsor	Sinovac Life Sciences Co., Ltd.
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	7,000
Start date	30 October 2022
Primary completion	31 December 2022
Estimated completion	31 March 2023
Sites	1 location across China

Drugs / interventions tested

SA58 Nasal Spray — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Sinovac Life Sciences Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open, blank controlled clinical trial to evaluate the efficacy and safety of SA58 nasal spray in the prevention COVID-19 infection among health care workers at high risk of SARS-CoV-2 infection.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Delivery of biologics: Topical administration.
Kulchar RJ, Singh R, Ding S, Alexander E, et al · · 2023 · cited 31× · PMID 37690380 · DOI 10.1016/j.biomaterials.2023.122312
Safety and Effectiveness of SA58 Nasal Spray Against COVID-19 Infection in Medical Personnel: An Open-Label, Blank-Controlled Study - Hohhot City, Inner Mongolia Autonomous Region, China, 2022.
Si S, Jin C, Li J, Cao Y, et al · · 2023 · cited 5× · PMID 37006441 · DOI 10.46234/ccdcw2023.040
Safety and Effectiveness of SA58 Nasal Spray against COVID-19 Infection in Medical Personnel:An Open-label, Blank-controlled Study
Si S, Jin C, Li J, Cao Y, et al · · 2022 · DOI 10.1101/2022.12.27.22283698

Verify or expand the search:

Other trials of SA58 Nasal Spray

Trials testing the same drug.

NCT05667714 — Efficacy and Safety of SA58 Nasal Spray in Close Contact With COVID-19 People · NA · unknown

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Sinovac Life Sciences Co., Ltd. trials

Trials by the same sponsor.

NCT07374510 — Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine · Phase 1 · not yet recruiting
NCT06967272 — PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells) · Phase 2 · recruiting
NCT06617715 — Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine · Phase 3 · recruiting
NCT06550830 — Clinical Trial of PCV24 in Children Aged 2-17 Years · Phase 1 · completed
NCT06474377 — Clinical Trial of PCV24 in Adults · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05664919 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sinovac Life Sciences Co., Ltd.
Last refreshed: 12 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05664919.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing